Therapy Dogs Supported Radiotherapy in Cancer Patients Treated with MR Linac – Preliminary Results

Autor: Kucuktulu, E., Atalar, B., Topbas, M., Bilir, B., Bicakci, A., Yilmaz, B., Culha, A., Ustuner, O., Culha, A.K., Uyar, M., Ugurluer, G., Ozyar, E.

Publikováno v: In International Journal of Radiation Oncology, Biology, Physics 1 October 2024 120(2) Supplement:e351-e351

Potential Antithrombotic Effects of Bupivacaine in Malignancies: An In Vitro Assesment using Thromboelastography.

Autor: BILIR, B. A.¹, AKAY, M. O.², CEYHAN, D.¹ drdceyhan@gmail.com, MUTLU, F. S.³

Publikováno v: Indian Journal of Pharmaceutical Sciences. Jul/Aug2016, Vol. 78 Issue 4, p553-557. 5p.

EO5 - Factors affecting recurrence in nephron-sparing surgery and ablative methods in small kidney tumors (pT1a): Our single center experiences

Autor: Atacer, M.O., Bilir, B., Aktoz, T., Arda, E.

Publikováno v: In European Urology Open Science November 2022 45 Supplement 1:S6-S7

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3

Autor: Shiffman M. L., Suter F., Bacon B. R., Nelson D., Harley H., Sola R., Shafran S. D., Barange K., Lin A., Soman A., Zeuzem S., Crawford D., Leggett L., Roberts S., Weltman M., Greenbloom S., Menon K., Bourliere M., Brissot P., Bronowicki J. P., Doffoel M., Hezode C., Marcellin P., Tran A., Zarski J. P., Avci O., Berg T., Potthoff O., Rasenack J., Ross O., von Wagner M., Ascione A., Brunetto M., Bruno R., Bruno S., Cane E., Aguilar J., Barcena R., Diago M., Enriquez J., Garcia Samaniego J., Moreno R., Planas R., Rincon D., Testillano M., Anand B., Bilir B. Bahri, Balan V., Bank L., Barranco E., Berg C., Bernstein D., Bloom J., Bonkovsky H., Box T., Brau N., Bzowej N., Cassidy W., Clain D., Corasanti J., Davis M., DeJesus E., Delich P., Esposito S., Etzkorn K., Flora K., Fried M., Fromm H., Ghalib R., Gibas A., Godofsky E., Gompf S., Gordon S., Gordon F., Hammond G., Harrison S., Herrera J., Ho S., Howell C., Joshi S., Keeffe E., Kranz K., Kwo P., Lake Bakaar G., Larson A., Levin A., Lok A., Lucey M., Lyons M., Malet P., Malik P., Manch R., Mehra S., Mihas A., Mikolich D., Morgan T., Muir A., Nguyen R., Nunes D., Nyberg L., O'Brien C., Pappas S., Pauly M., Pedrosa M., Perkel M., Person J., Pockros P., Post A., Poulos J., Powell R., Raj V., Reed A., Reindollar R., Riley T., Rodriguez Torres M., Rubin R., Sahagun G., Schmidt W., Sepe T., Shaw Stiffel T., Sheikh A., Sherman K., Smith C., Stevens D., Sulkowski M., Toro D., Torres E., Tran T., Tsai N., Wohlman R., Wright W., Wruble L., Younossi Z., BRILLANTI, STEFANO

BACKGROUND: Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for 24 weeks. We conducted a large, randomized, multina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38d06d4d125b5f21e735f5226014a1f0
http://hdl.handle.net/11365/1070791